share_log

Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target

Benzinga ·  Jun 28, 2024 10:37

Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment